Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 2/20 | 0.63 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.61 |
| ▸ | CNR2 | P34972 | 1/20 | 0.56 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.56 |
| ▸ | RXRA | P19793 | 1/20 | 0.56 |
| ▸ | RXRB | P28702 | 1/20 | 0.56 |
| ▸ | BCL2 | P10415 | 1/20 | 0.56 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.55 |
| ▸ | PRKCI | P41743 | 1/20 | 0.53 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.53 |
| ▸ | FNTA | P49354 | 2/20 | 0.52 |
| ▸ | FNTB | P49356 | 2/20 | 0.52 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.52 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.52 |
| ▸ | KDM5A | P29375 | 1/20 | 0.52 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.52 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.52 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL129182 | 0.88 | FOLH1 (0.68) | NR4A2FOLH1 | |
| SCHEMBL5154732 | 0.87 | KMO (0.67) | KMOACMSDNR4A2RXRARXRB | |
| SCHEMBL4140814 | 0.87 | BCL2 (0.73) | KMOACMSDRXRARXRBBCL2 | |
| SCHEMBL29784246 | 0.87 | BCL2 (0.73) | KMOACMSDRXRARXRBBCL2 | |
| Water SCHEMBL7811295 | 0.86 | FOLH1 (0.66) | NR4A2FOLH1MRGPRX4 | |
| SCHEMBL30725957 | 0.84 | KMO (0.86) | KMORXRARXRB | |
| SCHEMBL29904709 | 0.84 | KMO (0.86) | KMORXRARXRB | |
| SCHEMBL71238 | 0.84 | KMO (0.86) | KMORXRARXRB | |
| SCHEMBL5593093 | 0.84 | PRKCI (0.53) | KMOACMSDCNR2NR4A2BCL2 | |
| SCHEMBL12894987 | 0.84 | BCL2 (0.78) | KMONR4A2RXRARXRBBCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007519744-A | — | — | 2007-07-19 | — | — | JP | claimed |
| US-20070088001-A1 | Silinane compounds as cysteine protease inhibitors | QUEST DIAGNOSTICS INVESTMENTS LLC | 2007-04-19 | — | — | US | claimed |
| EP-1716158-A2 | SILINANE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | Schering Aktiengesellschaft (DE) | 2006-11-02 | — | — | EP | claimed |
| WO-2005074904-A2 | SILINANE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-08-18 | — | — | WO | claimed |
| US-20210139521-A1 | DIARYL TREHALOSE COMPOUNDS AND USES THEREOF | THE UNIV OF MONTANA (US) | 2021-05-13 | — | — | US | disclosed |
| US-20070088001-A1 | Silinane compounds as cysteine protease inhibitors | QUEST DIAGNOSTICS INVESTMENTS LLC | 2007-04-19 | — | — | US | disclosed |
| EP-0758243-B1 | BINDING OF E-SELECTIN, P-SELECTIN OR L-SELECTIN TO SIALYL-LEWISx OR SIALYL-LEWISa | TEXAS BIOTECHNOLOGY CORP (US) | 2003-03-12 | — | — | EP | disclosed |
| EP-0758243-A4 | BINDING OF E-SELECTIN, P-SELECTIN OR L-SELECTIN TO SIALYL-LEWISx OR SIALYL-LEWISa | TEXAS BIOTECHNOLOGY CORP (US) | 1997-08-20 | — | — | EP | disclosed |
| CN-1151117-A | Binding of E-selectin, P-selectin or L-selectin to sialyl-Lewis(x) or sialyl-lewis(a) | TAXAS BIOTECHNOLOGY CORP (US) | 1997-06-04 | — | — | CN | disclosed |
| EP-0758243-A1 | BINDING OF E-SELECTIN, P-SELECTIN OR L-SELECTIN TO SIALYL-LEWISx OR SIALYL-LEWISa | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1997-02-19 | — | — | EP | disclosed |
| WO-1995029682-A1 | BINDING OF E-SELECTIN, P-SELECTIN OR L-SELECTIN TO SIALYL-LEWISx OR SIALYL-LEWIS?a¿ | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1995-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139521-A1 | DIARYL TREHALOSE COMPOUNDS AND USES THEREOF | TREH, STT3B, DDOST | KMO 4115/4885ACMSD 931/4885CNR2 4469/4885 |
| US-20070088001-A1 | Silinane compounds as cysteine protease inhibitors | CTSV, CTSB, CTSS | KMO 1212/4885ACMSD 3301/4885CNR2 2960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.